MAGEA9

Across TCGA pan-cancer cohorts, MAGEA9 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MAGEA9 data layer compared with 13 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher MAGEA9 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated MAGEA9 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

LUAD, LSCC, and HNSC are the cancer types where MAGEA9 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	DFS	Quartile	All	0.913	0.416	.021	6	view →
LSCC	DFS	Median	II,III,IV	0.236	0.984	.014	4	view →
HNSC	OS	Tertile	All	0.744	1.000	.017	4	view →
CCRCC	OS	Median	All	1.000	0.659	.031	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MAGEA9–LUAD (DFS)

Open the LUAD breakdown →